Phytohealth Corporation

As of June 30, 2026, Phytohealth Corporation carries a market capitalization of 2.40B, placing it among publicly traded companies globally. Its enterprise value stands at 1.83B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Phytohealth Corporation has 198.62M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 17.63, and the price-to-book ratio stands at 1.24.

These figures are as of June 30, 2026. The EV/Sales ratio of 12.78 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 1.83B versus a market cap of 2.40B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Phytohealth Corporation maintains a current ratio of 29.17, meaning it holds 29.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.90, indicating moderate leverage, while an interest coverage ratio of -275.66 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Phytohealth Corporation posted a negative return on equity (ROE) of -2.29, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -1.83, reflecting losses generated across the asset base. The company generates approximately 1.11M in revenue per employee across its workforce of 129.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.75 indicates how many times Phytohealth Corporation sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Phytohealth Corporation recorded 12,000.00 in income tax expense. The company reported a pretax loss of -92.41M and -43.37M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Phytohealth Corporation's stock has declined approximately 19.39% over the past 52 weeks. The 50-day moving average sits at 11.33, while the 200-day moving average is 12.39.

Over the twelve months ended June 30, 2026, Phytohealth Corporation generated 143.43M in revenue and converted that into -43.37M in net income, yielding earnings per share of -0.44. EBITDA reached -116.60M, while operating income came in at -164.42M.

As of June 30, 2026, Phytohealth Corporation holds 1.00B in cash and equivalents against 21.27M in total debt, resulting in a net debt position of -84.25M. Total book value stands at 1.94B, with working capital of 1.14B providing operational flexibility.

Phytohealth Corporation produced -15.14M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -4.41M in capital expenditures, free cash flow totaled -19.55M - equivalent to -0.09 per share.

Over the twelve months ended June 30, 2026, Phytohealth Corporation posted a gross margin of 33.10, reflecting its pricing power and cost economics. The operating margin of -114.63 and net profit margin of -30.24 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -0.77: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 0.45, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Phytohealth Corporation shareholders.

Phytohealth Corporation's most recent stock split took place on January 5, 2021 with a 193:199 split ratio.

As of June 30, 2026, Phytohealth Corporation has an Altman Z-Score of 25.00, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.